Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 9/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 4/20 | 0.32 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.31 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.31 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17794223 | 0.88 | PLA2G2C (0.37) | PLA2G2CLPAR1LPAR3LPAR2USP2 | |
| SCHEMBL14755325 | 0.85 | PLA2G2C (0.35) | PLA2G2CLPAR1LPAR3LPAR2USP2 | |
| SCHEMBL2632269 | 0.85 | PLA2G2C (0.35) | PLA2G2CLPAR1LPAR3LPAR2USP2 | |
| SCHEMBL2632262 | 0.81 | PLA2G2C (0.36) | PLA2G2CLPAR1LPAR3LPAR2USP2 | |
| SCHEMBL10816729 | 0.79 | LPAR1 (0.46) | PLA2G2CLPAR1LPAR3LPAR2USP2 | |
| SCHEMBL11302968 | 0.77 | LPAR1 (0.49) | PLA2G2CLPAR1LPAR3LPAR2USP2 | |
| SCHEMBL7784745 | 0.76 | USP2 (0.50) | PLA2G2CLPAR1LPAR3LPAR2USP2 | |
| SCHEMBL12386622 | 0.76 | TSHR (0.38) | PLA2G2CLPAR1LPAR3LPAR2USP2 | |
| SCHEMBL17794227 | 0.75 | PLA2G2C (0.36) | PLA2G2CLPAR1LPAR3LPAR2USP2 | |
| SCHEMBL10564674 | 0.75 | USP2 (0.53) | PLA2G2CLPAR1LPAR3LPAR2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158620-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20100317850-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-16 | — | — | US | disclosed |
| US-20090209755-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| WO-2009091016-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209755-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | PLA2G2C 1803/4885LPAR1 2634/4885LPAR3 2366/4885 |
| US-20100317850-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, APP, BACE2 | PLA2G2C 1411/4885LPAR1 2969/4885LPAR3 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.